Mirtazapine for the treatment of interferon-induced psychopathology.
Russo
Sascha
S
Boon
Jim C
JC
Korf
Jakob
J
Haagsma
Elizabeth B
EB
D000328:Adult; D000374:Aggression / Q000187:drug effects; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006526:Hepatitis C / Q000188:drug therapy / Q000523:psychology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D016899:Interferon-beta / Q000008:administration & dosage / Q000009:adverse effects*; D008297:Male; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000078785:Mirtazapine; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000523:psychology; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins; D012919:Social Behavior
D000929:Antidepressive Agents, Tricyclic; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D008803:Mianserin; D011092:Polyethylene Glycols; D016899:Interferon-beta; D000078785:Mirtazapine; C100416:peginterferon alfa-2a